Vaxcyte, Inc.
PCVX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $476,644 | $332,341 | $169,451 | $78,411 |
| G&A Expenses | $92,902 | $60,700 | $39,810 | $25,259 |
| SG&A Expenses | $92,902 | $60,700 | $39,810 | $25,259 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $75,000 | $22,995 | $0 |
| Operating Expenses | $569,546 | $468,041 | $232,256 | $103,670 |
| Operating Income | -$569,546 | -$468,041 | -$232,256 | -$103,670 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $105,619 | $65,775 | $8,771 | $3,593 |
| Pre-Tax Income | -$463,927 | -$402,266 | -$223,485 | -$100,077 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$463,927 | -$402,266 | -$223,485 | -$100,077 |
| % Margin | – | – | – | – |
| EPS | -3.8 | -4.14 | -3.44 | -1.93 |
| % Growth | 8.2% | -20.3% | -78.2% | – |
| EPS Diluted | -3.8 | -4.14 | -3.44 | -1.93 |
| Weighted Avg Shares Out | 121,997 | 97,158 | 64,878 | 51,922 |
| Weighted Avg Shares Out Dil | 121,997 | 97,158 | 64,878 | 51,922 |
| Supplemental Information | – | – | – | – |
| Interest Income | $109,994 | $62,907 | $8,356 | $344 |
| Interest Expense | $0 | $0 | $2 | $7 |
| Depreciation & Amortization | $15,845 | $10,171 | $9,453 | $3,457 |
| EBITDA | -$448,082 | -$392,095 | -$214,030 | -$96,613 |
| % Margin | – | – | – | – |